AU2017200329B2 — Sublingual apomorphine
Assigned to Sumitomo Pharma America Inc · Expires 2018-11-08 · 8y expired
What this patent protects
A pharmaceutical composition in unit dosage form formulated for sublingual administration, said unit dosage form having a first portion comprising an acid addition salt of apomorphine, or an apomorphine prodrug, and a second portion comprising a pH neutralizing agent.
USPTO Abstract
A pharmaceutical composition in unit dosage form formulated for sublingual administration, said unit dosage form having a first portion comprising an acid addition salt of apomorphine, or an apomorphine prodrug, and a second portion comprising a pH neutralizing agent.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.